Scharf, Christina
Weinelt, Ferdinand
Schroeder, Ines
Paal, Michael
Weigand, Michael
Zoller, Michael
Irlbeck, Michael
Kloft, Charlotte
Briegel, Josef
Liebchen, Uwe http://orcid.org/0000-0002-4375-0923
Clinical trials referenced in this document:
Documents that mention this clinical trial
Does the cytokine adsorber CytoSorb® reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study
https://doi.org/10.1186/s13613-022-01017-5
Funding for this research was provided by:
Medizinischen Fakultät, Ludwig-Maximilians-Universität München (FöFoLe No. 002)
Universitätsklinik München
Article History
Received: 1 September 2021
Accepted: 6 May 2022
First Online: 23 May 2022
Declarations
:
: Ethical approval and consent were obtained from the Institutional Review Board of the Medical Faculty of the Ludwig-Maximilians-Universität München (Munich, Germany) [registration No. 18–578].
: Not applicable.
: CK reports grants from an industry consortium (AbbVie Deutschland GmbH & Co. KG, AstraZeneca, Boehringer Ingelheim Pharma GmbH & Co. KG, Grünenthal GmbH, F. Hoffmann-La Roche Ltd, Merck KGaA and SANOFI) for the PharMetrX PhD program, the Innovative Medicines Initiative-Joint Undertaking ("DDMoRe”), Diurnal Ltd., the Federal Ministry of Education and Research within the Joint Programming Initiative on Antimicrobial Resistance Initiative (JPIAMR) and the European Commission within in the Horizon 2020 framework programme (“FAIR”), all outside the submitted work.